130 related articles for article (PubMed ID: 34089835)
21. The potential of CYP46A1 as a novel therapeutic target for neurological disorders: An updated review of mechanisms.
Alavi MS; Karimi G; Ghanimi HA; Roohbakhsh A
Eur J Pharmacol; 2023 Jun; 949():175726. PubMed ID: 37062503
[TBL] [Abstract][Full Text] [Related]
22. Pharmacologic stimulation of cytochrome P450 46A1 and cerebral cholesterol turnover in mice.
Mast N; Li Y; Linger M; Clark M; Wiseman J; Pikuleva IA
J Biol Chem; 2014 Feb; 289(6):3529-38. PubMed ID: 24352658
[TBL] [Abstract][Full Text] [Related]
23. Structural basis of drug binding to CYP46A1, an enzyme that controls cholesterol turnover in the brain.
Mast N; Charvet C; Pikuleva IA; Stout CD
J Biol Chem; 2010 Oct; 285(41):31783-95. PubMed ID: 20667828
[TBL] [Abstract][Full Text] [Related]
24. In silico and intuitive predictions of CYP46A1 inhibition by marketed drugs with subsequent enzyme crystallization in complex with fluvoxamine.
Mast N; Linger M; Clark M; Wiseman J; Stout CD; Pikuleva IA
Mol Pharmacol; 2012 Nov; 82(5):824-34. PubMed ID: 22859721
[TBL] [Abstract][Full Text] [Related]
25. Chromatin-modifying agents increase transcription of CYP46A1, a key player in brain cholesterol elimination.
Milagre I; Nunes MJ; Moutinho M; Rivera I; Fuso A; Scarpa S; Gama MJ; Rodrigues E
J Alzheimers Dis; 2010; 22(4):1209-21. PubMed ID: 20930312
[TBL] [Abstract][Full Text] [Related]
26. Detection and mass spectrometric characterization of novel long-term dehydrochloromethyltestosterone metabolites in human urine.
Sobolevsky T; Rodchenkov G
J Steroid Biochem Mol Biol; 2012 Feb; 128(3-5):121-7. PubMed ID: 22142641
[TBL] [Abstract][Full Text] [Related]
27. Increased Acetylcholine Levels and Other Brain Effects in 5XFAD Mice after Treatment with 8,14-Dihydroxy Metabolite of Efavirenz.
Mast N; Li Y; Pikuleva IA
Int J Mol Sci; 2022 Jul; 23(14):. PubMed ID: 35887013
[TBL] [Abstract][Full Text] [Related]
28. CYP46A1 activation by low-dose efavirenz enhances brain cholesterol metabolism in subjects with early Alzheimer's disease.
Lerner AJ; Arnold SE; Maxfield E; Koenig A; Toth ME; Fortin B; Mast N; Trombetta BA; Denker J; Pieper AA; Tatsuoka C; Raghupathy S; Pikuleva IA
Alzheimers Res Ther; 2022 Dec; 14(1):198. PubMed ID: 36581878
[TBL] [Abstract][Full Text] [Related]
29. New Therapeutic Targets for Brain Function and Disease.
van Lier JE
J Med Chem; 2020 Jun; 63(12):6474-6476. PubMed ID: 31845585
[TBL] [Abstract][Full Text] [Related]
30. Neuronal cholesterol metabolism increases dendritic outgrowth and synaptic markers via a concerted action of GGTase-I and Trk.
Moutinho M; Nunes MJ; Correia JC; Gama MJ; Castro-Caldas M; Cedazo-Minguez A; Rodrigues CM; Björkhem I; Ruas JL; Rodrigues E
Sci Rep; 2016 Aug; 6():30928. PubMed ID: 27491694
[TBL] [Abstract][Full Text] [Related]
31. CYP46A1 protects against NMDA-mediated excitotoxicity in Huntington's disease: Analysis of lipid raft content.
Boussicault L; Kacher R; Lamazière A; Vanhoutte P; Caboche J; Betuing S; Potier MC
Biochimie; 2018 Oct; 153():70-79. PubMed ID: 30107216
[TBL] [Abstract][Full Text] [Related]
32. CYP46A1 gene therapy deciphers the role of brain cholesterol metabolism in Huntington's disease.
Kacher R; Lamazière A; Heck N; Kappes V; Mounier C; Despres G; Dembitskaya Y; Perrin E; Christaller W; Sasidharan Nair S; Messent V; Cartier N; Vanhoutte P; Venance L; Saudou F; Néri C; Caboche J; Betuing S
Brain; 2019 Aug; 142(8):2432-2450. PubMed ID: 31286142
[TBL] [Abstract][Full Text] [Related]
33. Identification of CYP46A1 as a new regulator of lipid metabolism through CRISPR-based whole-genome screening.
Si Z; Guan X; Teng X; Peng X; Wan Z; Li Q; Chen G; Tan J; Li J
FASEB J; 2020 Oct; 34(10):13776-13791. PubMed ID: 32816363
[TBL] [Abstract][Full Text] [Related]
34. Retinal Vascular Abnormalities and Microglia Activation in Mice with Deficiency in Cytochrome P450 46A1-Mediated Cholesterol Removal.
Saadane A; Mast N; Trichonas G; Chakraborty D; Hammer S; Busik JV; Grant MB; Pikuleva IA
Am J Pathol; 2019 Feb; 189(2):405-425. PubMed ID: 30448403
[TBL] [Abstract][Full Text] [Related]
35. [Application of microbial enzymes in studies of steroid metabolism (author's transl)].
Schlegel J; Schubert K
Acta Microbiol Acad Sci Hung; 1975; 22(4):397-402. PubMed ID: 818880
[TBL] [Abstract][Full Text] [Related]
36. 24S-hydroxycholesterol and cholesterol-24S-hydroxylase (CYP46A1) in the retina: from cholesterol homeostasis to pathophysiology of glaucoma.
Fourgeux C; Bron A; Acar N; Creuzot-Garcher C; Bretillon L
Chem Phys Lipids; 2011 Sep; 164(6):496-9. PubMed ID: 21531213
[TBL] [Abstract][Full Text] [Related]
37. The synthesis of 4-chloro-17β-hydroxymethyl-17α-methyl-18-norandrosta-4,13-diene-3α-ol - Proposed long term metabolite (M4) of oralturinabol.
Shostko DY; Liubina AI; Kozyrkov YY; Beliaev SA
Steroids; 2020 Jun; 158():108601. PubMed ID: 32084502
[TBL] [Abstract][Full Text] [Related]
38. Molecular Basis of the Recognition of Cholesterol by Cytochrome P450 46A1 along the Major Access Tunnel.
Shi N; Zheng Q; Zhang H
ACS Chem Neurosci; 2022 May; 13(10):1526-1533. PubMed ID: 35438962
[TBL] [Abstract][Full Text] [Related]
39. Studies on the transcriptional regulation of cholesterol 24-hydroxylase (CYP46A1): marked insensitivity toward different regulatory axes.
Ohyama Y; Meaney S; Heverin M; Ekström L; Brafman A; Shafir M; Andersson U; Olin M; Eggertsen G; Diczfalusy U; Feinstein E; Björkhem I
J Biol Chem; 2006 Feb; 281(7):3810-20. PubMed ID: 16321981
[TBL] [Abstract][Full Text] [Related]
40. CYP46A1, the rate-limiting enzyme for cholesterol degradation, is neuroprotective in Huntington's disease.
Boussicault L; Alves S; Lamazière A; Planques A; Heck N; Moumné L; Despres G; Bolte S; Hu A; Pagès C; Galvan L; Piguet F; Aubourg P; Cartier N; Caboche J; Betuing S
Brain; 2016 Mar; 139(Pt 3):953-70. PubMed ID: 26912634
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
